Literature DB >> 24787007

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

Chen Shochat1, Noa Tal2, Vitalina Gryshkova3, Yehudit Birger4, Obul R Bandapalli5, Giovanni Cazzaniga6, Nava Gershman7, Andreas E Kulozik5, Andrea Biondi6, Marc R Mansour8, Jean-Claude Twizere9, Martina U Muckenthaler5, Nir Ben-Tal10, Stefan N Constantinescu3, Dani Bercovich11, Shai Izraeli2.   

Abstract

Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor α (IL7R) or cytokine receptor-like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787007     DOI: 10.1182/blood-2013-10-529685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

2.  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Authors:  Shuo-Chieh Wu; Loretta S Li; Nadja Kopp; Joan Montero; Bjoern Chapuy; Akinori Yoda; Amanda L Christie; Huiyun Liu; Alexandra Christodoulou; Diederik van Bodegom; Jordy van der Zwet; Jacob V Layer; Trevor Tivey; Andrew A Lane; Jeremy A Ryan; Samuel Y Ng; Daniel J DeAngelo; Richard M Stone; David Steensma; Martha Wadleigh; Marian Harris; Emeline Mandon; Nicolas Ebel; Rita Andraos; Vincent Romanet; Arno Dölemeyer; Dario Sterker; Michael Zender; Scott J Rodig; Masato Murakami; Francesco Hofmann; Frank Kuo; Michael J Eck; Lewis B Silverman; Stephen E Sallan; Anthony Letai; Fabienne Baffert; Eric Vangrevelinghe; Thomas Radimerski; Christoph Gaul; David M Weinstock
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

3.  Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Authors:  Marc R Mansour; Casie Reed; Amy R Eisenberg; Jen-Chieh Tseng; Jean-Claude Twizere; Sarah Daakour; Akinori Yoda; Scott J Rodig; Noa Tal; Chen Shochat; Alla Berezovskaya; Daniel J DeAngelo; Stephen E Sallan; David M Weinstock; Shai Izraeli; Andrew L Kung; Alex Kentsis; A Thomas Look
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

Review 4.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

Review 5.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

Review 6.  The common γ-chain cytokine receptor: tricks-and-treats for T cells.

Authors:  Adam T Waickman; Joo-Young Park; Jung-Hyun Park
Journal:  Cell Mol Life Sci       Date:  2015-10-14       Impact factor: 9.261

7.  IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.

Authors:  Keishi Adachi; Yosuke Kano; Tomohiko Nagai; Namiko Okuyama; Yukimi Sakoda; Koji Tamada
Journal:  Nat Biotechnol       Date:  2018-03-05       Impact factor: 54.908

8.  Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.

Authors:  Rathana Kim; Nicolas Boissel; Aurore Touzart; Thibaut Leguay; Florian Thonier; Xavier Thomas; Emmanuel Raffoux; Françoise Huguet; Patrick Villarese; Cécile Fourrage; Loïc Passini; Mathilde Hunault; Stéphane Lepretre; Patrice Chevallier; Thorsten Braun; Véronique Lhéritier; Sylvain Chantepie; Sébastien Maury; Martine Escoffre; Emmanuelle Tavernier; Yves Chalandon; Carlos Graux; Elizabeth Macintyre; Norbert Ifrah; Vahid Asnafi; Hervé Dombret; Ludovic Lhermitte
Journal:  Leukemia       Date:  2020-01-28       Impact factor: 11.528

9.  Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Yongjin Li; Kathryn G Roberts; Stephanie M Dobson; Jaeseung C Kim; Debbie Payne-Turner; Richard C Harvey; Marcus Valentine; Kelly McCastlain; John Easton; Donald Yergeau; Laura J Janke; Ying Shao; I-Ming L Chen; Michael Rusch; Sasan Zandi; Steven M Kornblau; Marina Konopleva; Elias Jabbour; Elisabeth M Paietta; Jacob M Rowe; Ching-Hon Pui; Julie Gastier-Foster; Zhaohui Gu; Shalini Reshmi; Mignon L Loh; Janis Racevskis; Martin S Tallman; Peter H Wiernik; Mark R Litzow; Cheryl L Willman; John D McPherson; James R Downing; Jinghui Zhang; John E Dick; Stephen P Hunger; Charles G Mullighan
Journal:  Cancer Cell       Date:  2016-02-08       Impact factor: 31.743

Review 10.  Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Authors:  Thomas Shum; Robert L Kruse; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2018-05-14       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.